NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

EB-101:到2030年考慮新藥和市場預測

EB 101- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959708
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
EB-101:到2030年考慮新藥和市場預測 EB 101- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

EB-101是一種自遺傳修飾的細胞療法,用於治療隱性營養不良性表皮囊泡性疾病(RDEB),這是一種罕見疾病,尚無批准的治癒方法,目前正在接受III期臨床試驗。

本報告調查了EB-101在美國,德國,法國,意大利,西班牙,英國和日本的七個主要國家的市場,並顯示了2030年的前景。它提供了諸如評估,SWOT分析,競爭對手概況和其他新治療等信息。

調查範圍

  • 全面的產品概述,包括產品描述,作用機理,劑量和給藥方法,研發活動
  • 開發活動的詳細信息,例如法規批准程序的里程碑
  • 美國,歐洲和日本的藥物研發細節
  • 包括EB-101到期日期在內的專利信息
  • 到2030年EB-101的銷售預測
  • 開發後期有關新治療劑的全面信息(第三階段)
  • 分析師的考慮和SWOT分析

報告重點

  • 未來,由於持續的研發和全球醫療費用的增長,表皮水泡的市場格局將發生巨大變化,並且由於市場的擴大,預計會有更多的製藥公司進入該市場。
  • 公司和研究人員正在尋找增加EB-101優勢的機會。目前正在開發的治療方法集中於治療/改善疾病的新方法。
  • 與EB-101競爭的新競爭產品已經出現,並有望在不久的將來對市場產生重大影響。

本報告解決的主要問題

  • 哪家公司正在開發EB-101?
  • EB-101的開發中使用了什麼技術?
  • EB-101的產品類型,給藥途徑和作用機理是什麼?
  • 臨床試驗的狀態和完成日期是什麼時候?
  • 與EB-101的開發有關的主要動向是什麼,例如合作,合併,收購和許可?
  • EB-101的主要規格是什麼?
  • EB-101的市場前景如何?
  • 到目前為止,EB-101的歷史是什麼?
  • 對EB-101在美國,德國,法國,意大利,西班牙,英國和日本的銷量有何預測?
  • 還有哪些其他新產品可用?如何與這些產品競爭?
  • 在開發後期,目前有哪些新的治療劑?

目錄

第1章藥物概述

  • 產品詳細信息
  • 作用機理
  • 藥物和管理
  • 研發活動
    • 臨床發展
    • 安全性和有效性
  • 其他發展活動

第2章市場評估

  • 7個主要國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 意大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章SWOT分析

第4章分析師的觀點

第5章市場競爭

第6章其他新補救措施

第7章附錄

第8章報表購買選項

目錄
Product Code: DIDM0059

"EB 101- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the EB 101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

EB-101 is an autologous, gene-corrected cell therapy currently being investigated in the pivotal Phase 3 VIITALTM study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy. The EB-101 VIITALTM study is a multi-center, randomized clinical trial enrolling 10 to 15 RDEB patients with approximately 30 large, chronic wound sites treated in total. Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient's own skin cells (keratinocytes and its progenitors) and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing. Abeona produces EB-101 for the VIITALTM study at its fully-functional gene and cell therapy manufacturing facility in Cleveland, OH. In a Phase 1/2a clinical trial, EB-101 provided durable wound healing for RDEB patients lasting 2+ to 5+ years, including for the largest, most challenging wounds that affect the majority of the RDEB population.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around EB 101.
  • The report contains forecasted sales for EB 101 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Epidermolysis bullosa.
  • The report also features the SWOT analysis with analyst insights and key findings of EB 101.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EB 101 Analytical Perspective by DelveInsight

  • In-depth EB 101 Market Assessment

This report provides a detailed market assessment of EB 101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • EB 101 Clinical Assessment

The report provides the clinical trials information of EB 101 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Epidermolysis bullosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence EB 101 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Epidermolysis bullosa are giving market competition to EB 101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of EB 101.
  • Our in-depth analysis of the forecasted sales data of EB 101 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EB 101.

Key Questions:

  • Which company is developing EB 101 along with the phase of the clinical study?
  • What is the technology utilized in the development of EB 101?
  • What is the product type, route of administration and mechanism of action of EB 101?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EB 101 development?
  • What are the key designations that have been granted to EB 101?
  • What is the forecasted market scenario of EB 101?
  • What is the history of EB 101 and what is its future?
  • What is the forecasted sales of EB 101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to EB 101?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 EB 101, Description
  • Table 2 EB 101, Clinical Trial Description
  • Table 3 EB 101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of EB 101
  • Figure 2 Patent Details, EB 101
  • Figure 3 EB 101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 EB 101, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 EB 101, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 EB 101, Japan Market Size from 2020 to 2030 (in Millions USD)